Asian Pacific Journal of Cancer Prevention

Asian Pacific Journal of Cancer Prevention (아시아태평양암예방학회)
권호 표지
DOI QR코드

DOI QR Code

Prognostic Values of Various Clinical Factors and Genetic Subtypes for Diffuse Large B-cell lymphoma Patients: A Retrospective Analysis of 227 Cases

  • Zhou, De (Department of Hematology, Bone Marrow Transplant Center, the First Affiliated Hospital of Medical School of Zhejiang University) ;
  • Xie, Wan-Zhuo (Department of Hematology, Bone Marrow Transplant Center, the First Affiliated Hospital of Medical School of Zhejiang University) ;
  • Hu, Ke-Yue (Department of Hematology, Bone Marrow Transplant Center, the First Affiliated Hospital of Medical School of Zhejiang University) ;
  • Huang, Wei-Jia (Department of Hematology, Bone Marrow Transplant Center, the First Affiliated Hospital of Medical School of Zhejiang University) ;
  • Wei, Guo-Qing (Department of Hematology, Bone Marrow Transplant Center, the First Affiliated Hospital of Medical School of Zhejiang University) ;
  • He, Jing-Song (Department of Hematology, Bone Marrow Transplant Center, the First Affiliated Hospital of Medical School of Zhejiang University) ;
  • Shi, Ji-Min (Department of Hematology, Bone Marrow Transplant Center, the First Affiliated Hospital of Medical School of Zhejiang University) ;
  • Luo, Yi (Department of Hematology, Bone Marrow Transplant Center, the First Affiliated Hospital of Medical School of Zhejiang University) ;
  • Li, Li (Department of Hematology, Bone Marrow Transplant Center, the First Affiliated Hospital of Medical School of Zhejiang University) ;
  • Zhu, Jing-Jing (Department of Hematology, Bone Marrow Transplant Center, the First Affiliated Hospital of Medical School of Zhejiang University) ;
  • Zhang, Jie (Department of Hematology, Bone Marrow Transplant Center, the First Affiliated Hospital of Medical School of Zhejiang University) ;
  • Lin, Mao-Fang (Department of Hematology, Bone Marrow Transplant Center, the First Affiliated Hospital of Medical School of Zhejiang University) ;
  • Ye, Xiu-Jin (Department of Hematology, Bone Marrow Transplant Center, the First Affiliated Hospital of Medical School of Zhejiang University) ;
  • Cai, Zhen (Department of Hematology, Bone Marrow Transplant Center, the First Affiliated Hospital of Medical School of Zhejiang University) ;
  • Huang, He (Department of Hematology, Bone Marrow Transplant Center, the First Affiliated Hospital of Medical School of Zhejiang University)
  • Published : 2013.02.28
Download PDF
⟨ Previous Next ⟩

Abstract

Aim: To analyze the significance of different clinical factors for prognostic prediction in diffuse large B-cell lymphoma (DLBCL) patients. Methods: Two hundred and twenty-seven DLBCL patients were retrospectively reviewed. Patients were managed with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) regimen or rituximab plus the CHOP (RCHOP) regimen. Results: Lactate dehydrogenase (LDH), ${\beta}2$-microglobulin (${\beta}2$-M), B symptoms, Ann Arbor stage and genetic subtypes were statistically relevant in predicting the prognosis of the overall survival (OS). In the CHOP group, the OS in patients with germinal center B-cell-like (GCB)(76.2%) was significantly higher than that of the non-GCB group (51.9%, P=0.032). With RCHOP management, there was no statistical difference in OS between the GCB (88.4%) and non-GCB groups (81.9%, P=0.288). Conclusion: Elevated LDH and ${\beta}2$-M levels, positive B symptoms, Ann Arbor stage III/IV, and primary nodal lymphoma indicate an unfavorable prognosis of DLBCL patients. Patients with GCB-like DLBCL have a better prognosis than those with non-GCB when treated with the CHOP regimen. The RCHOP treatment with the addition of rituximab can improve the prognosis of patients with DLBCL.

Keywords

References

  1. Alizadeh AA, Eisen MB, Davis RE, et al (2000). Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature, 403, 503-11. https://doi.org/10.1038/35000501
  2. Bodoor K, Matalka I, Hayajneh R, Haddad Y, Gharaibeh W (2012). Evaluation of BCL-6, CD10, CD138 and MUM-1 expression in diffuse large B-cell lymphoma patients: CD138 is a Marker of Poor Prognosis. Asian Pac J Cancer Prev, 13, 3037-46. https://doi.org/10.7314/APJCP.2012.13.7.3037
  3. Chen Y, Zhang H, Xu A, et al (2006). Elevation of serum l-lactate dehydrogenase B correlated with the clinical stage of lung cancer. Lung Cancer, 54, 95-102. https://doi.org/10.1016/j.lungcan.2006.06.014
  4. Conconi A, Zucca E, Roggero E, et al (2000). Prognostic models for diffuse large B-cell lymphoma. Hematol Oncol, 18, 61-73 https://doi.org/10.1002/1099-1069(200006)18:2<61::AID-HON658>3.0.CO;2-I
  5. Cunningham BA, Wang JL, Berggard I, Peterson PA (1973). The complete amino acid sequence of beta 2-microglobulin. Biochemistry, 12, 4811-22. https://doi.org/10.1021/bi00748a001
  6. Gross M, Top I, Laux I, et al (2007). Beta-2-microglobulin is an androgen-regulated secreted protein elevated in serum of patients with advanced prostate cancer. Clin Cancer Res, 13, 1979-86. https://doi.org/10.1158/1078-0432.CCR-06-1156
  7. Gussow D, Rein R, Ginjaar I, et al (1987). The human beta 2-microglobulin gene. Primary structure and definition of the transcriptional unit. J Immunol, 139, 3132-8.
  8. Hassan U, Mushtaq A, Mamoon N, et al (2012). Prognostic sub-grouping of diffuse large B-cell lymphomas into germinal centre and post germinal centre groups by immunohistochemistry after 6 cycles of chemotherapy. Asian Pac J Cancer Prev, 13, 1341-7. https://doi.org/10.7314/APJCP.2012.13.4.1341
  9. Hemmingsen L, Skaarup P (1977). Urinary excretion of ten plasma proteins in patients with renal carcinoma. Scand J Urol Nephro, 11, 41-6. https://doi.org/10.3109/00365597709179690
  10. Karan D, Kelly DL, Rizzino A, Lin MF, Batra SK (2002). Expression profile of differentially-regulated genes during progression of androgen-independent growth in human prostate cancer cells. Carcinogenesis, 23, 967-75. https://doi.org/10.1093/carcin/23.6.967
  11. Koukourakis MI, Giatromanolaki A, Sivridis E, Gatter KC, Harris AL (2006). Lactate dehydrogenase 5 expression in operable colorectal cancer: strong association with survival and activated vascular endothelial growth factor pathway--a report of the Tumour Angiogenesis Research Group. J Clin Oncol, 24, 4301-8. https://doi.org/10.1200/JCO.2006.05.9501
  12. Krol AD, le CS, Snijder S, et al (2003). Primary extranodal non-Hodgkin's lymphoma (NHL): the impact of alternative definitions tested in the Comprehensive Cancer Centre West population-based NHL registry. Ann Oncol, 14, 131-9. https://doi.org/10.1093/annonc/mdg004
  13. Lenz G, Wright G, Dave SS, et al (2008). Stromal gene signatures in large-B-cell lymphomas. N Engl J Med, 359, 2313-23. https://doi.org/10.1056/NEJMoa0802885
  14. Li X, Liu Z, Cao J, et al (2012). Rituximab in combination with CHOP chemotherapy for the treatment of diffuse large B cell lymphoma in China: a 10-year retrospective follow-up analysis of 437 cases from Shanghai Lymphoma Research Group. Ann Hematol, 91, 837-45. https://doi.org/10.1007/s00277-011-1375-0
  15. Naz E, Mirza T, Danish F (2011). Clinicopathologic evaluation of subgroups of diffuse large B cell lymphoma by immunohistochemistry. Asian Pac J Cancer Prev, 12, 3335-9.
  16. Pedersen LO, Hansen AS, Olsen AC, et al (1994). The interaction between beta 2-microglobulin (beta 2m) and purified class-I major histocompatibility (MHC) antigen. Scand J Immunol, 39, 64-72. https://doi.org/10.1111/j.1365-3083.1994.tb03341.x
  17. Poulsen CB, Borup R, Nielsen FC, et al (2005). Microarray-based classification of diffuse large B-cell lymphoma. Eur J Haematol, 74, 453-65. https://doi.org/10.1111/j.1600-0609.2005.00429.x
  18. Rosenwald A, Wright G, Chan WC, et al (2002). The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med, 346, 1937-47. https://doi.org/10.1056/NEJMoa012914
  19. Shipp MA, Ross KN, Tamayo P, et al (2002). Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning. Nat Med, 8, 68-74. https://doi.org/10.1038/nm0102-68
  20. Shuster J, Gold P, Poulik MD (1976). Beta 2-microglogulin levels in cancerous and other disease states. Clin Chim Acta, 67, 307-13. https://doi.org/10.1016/0009-8981(76)90339-9
  21. Teasdale C, Mander AM, Fifield R, et al (1977). Serum beta2-microglobulin in controls and cancer patients. Clin Chim Acta, 78, 135-43. https://doi.org/10.1016/0009-8981(77)90346-1
  22. Townsend AR, Rothbard J, Gotch FM, et al (1986).The epitopes of influenza nucleoprotein recognized by cytotoxic T lymphocytes can be defined with short synthetic peptides. Cell, 44, 959-68. https://doi.org/10.1016/0092-8674(86)90019-X
  23. Ward DG, Nyangoma S, Joy H, et al (2008). Proteomic profiling of urine for the detection of colon cancer. Proteome Sci, 6, 19. https://doi.org/10.1186/1477-5956-6-19
  24. Yang J, Qian J, Wezeman M, et al (2006). Targeting beta2-microglobulin for induction of tumor apoptosis in human hematological malignancies. Cancer Cell, 10, 295-307. https://doi.org/10.1016/j.ccr.2006.08.025

Cited by

  1. The Expression of CD30 Based on Immunohistochemistry Predicts Inferior Outcome in Patients with Diffuse Large B-Cell Lymphoma vol.10, pp.5, 2015, https://doi.org/10.1371/journal.pone.0126615
  2. Secondary cutaneous lymphoma: comparative clinical features and survival outcome analysis of 106 cases according to lymphoma cell lineage vol.173, pp.1, 2015, https://doi.org/10.1111/bjd.13582
  3. Genome Analysis of Osteosarcoma Progression Samples Identifies FGFR1 Overexpression as a Potential Treatment Target and CHM as a Candidate Tumor Suppressor Gene vol.11, pp.9, 2016, https://doi.org/10.1371/journal.pone.0163859
  4. Determining protein biomarkers for DLBCL using FFPE tissues from HIV negative and HIV positive patients vol.47, pp.6, 2016, https://doi.org/10.1007/s10735-016-9695-y